MYC Is a Clinically Significant Driver of mTOR Inhibitor Resistance in Breast Cancer

Researchers showed that MYC activation drove resistance to mTOR inhibitors in breast cancer. MYC status was significantly associated with poor response to everolimus therapy in metastatic breast cancer patients.